Clinical Trial

A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated August 14, 2023 (before its estimated August 5, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a randomized, double-blind, phase III clinical study to compare the efficacy and safety of AK104 combined chemotherapy versus Tislelizumab combined chemotherapy in first-line treatment of Locally advanced or metastatic NSCLC with PD-L1 TPS \< 1%.
Trial Details
NCT Number NCT05990127
Lead Sponsor Akeso
Conditions Locally Advanced or Metastatic NSCLC
Enrollment 642 participants
Start Date 2023-11-14
Primary Completion 2025-08-05 (estimated)
Study Completion 2026-11-28 (estimated)
Updated on ClinicalTrials.gov 2023-08-14